-
Mashup Score: 2
The FDA has approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in metastatic non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 469
The head of NASA said a report that Elon Musk has been in regular contact with Russian President Vladimir Putin should be investigated — and if it’s true, “would be concerning” for a host of U.S. agencies.
Source: www.politico.comCategories: General Medicine News, Hem/OncsTweet-
RT @politico: NASA chief: Reported Musk and Putin conversations ‘should be investigated’ https://t.co/qCQ8kNmQKu
-
-
Mashup Score: 2
The FDA has approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in metastatic non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet-
FDA Approves Optune Lua for Metastatic NSCLC After Platinum-Based Chemotherapy https://t.co/c0UM26tVee via @onclive
-
-
Mashup Score: 4Meta Introduces Spirit LM open source model that combines text and speech inputs/outputs - 1 month(s) ago
Spirit LM Expressive incorporates emotional cues into its speech generation and can detect and reflect anger, surprise, or joy.
Source: venturebeat.comCategories: General Medicine News, Hem/OncsTweet-
RT @VentureBeat: Meta Introduces Spirit LM open source model that combines text and speech inputs/outputs https://t.co/kXdZ7uxvaB
-
-
Mashup Score: 33Nvidia just dropped a new AI model that crushes OpenAI’s GPT-4—no big launch, just big results - 1 month(s) ago
Nvidia quietly launched a groundbreaking AI model that surpasses OpenAI’s GPT-4 and Anthropic’s Claude 3.5, signaling a major shift in the competitive landscape of artificial intelligence.
Source: venturebeat.comCategories: General Medicine News, Hem/OncsTweet-
RT @VentureBeat: Nvidia just dropped a new AI model that crushes OpenAI’s GPT-4—no big launch, just big results https://t.co/rEcBqMjMyj
-
-
Mashup Score: 3A Biomedical Researcher on AI's Promises and Pitfalls - 1 month(s) ago
A conversation with Marinka Zitnik, assistant professor of biomedical informatics in the Blavatnik Institute at HMS
Source: magazine.hms.harvard.eduCategories: General Medicine News, Hem/OncsTweet-
RT @zakkohane: I'll have what she's having. @harvardmed @harvardmagazine https://t.co/VCQOrT2DDO
-
-
Mashup Score: 2
The FDA has approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in metastatic non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet-
FDA Approves Optune Lua for Metastatic NSCLC After Platinum-Based Chemotherapy https://t.co/c0UM26tVee via @onclive
-
-
Mashup Score: 10Exploring AI-Based Clinical Documentation With DAX Copilot - 1 month(s) ago
Artificial intelligence expert Arturo Loaiza-Bonilla, MD, discusses the benefits of AI-based clinical notes.
Source: www.medscape.comCategories: General Medicine News, Hem/OncsTweet-
Is AI-based Clinical Documentation the Future? - our most recent coming at @Medscape @WebMD @NuanceInc @Microsoft #ambientAI https://t.co/e21w9aqvVz
-
-
Mashup Score: 1Meloni: Sammy Basso è stato un esempio straordinario di coraggio, fede e positività - Agenzia Nova - 2 month(s) ago
Meloni: Sammy Basso è stato un esempio straordinario di coraggio, fede e positività Leggi le notizie su Agenzia Nova
Source: www.agenzianova.comCategories: General Medicine News, Hem/OncsTweet-
Meloni: Sammy Basso è stato un esempio straordinario di coraggio, fede e positività https://t.co/Hw4hppB0Rm via @agenzia_nova
-
-
Mashup Score: 1Rune Labs’ StrivePD Nearly Halves ER Visits for Parkinson’s Patients in Program with Kaiser Permanente - 2 month(s) ago
Rune Labs, a leader in precision medicine for Parkinson’s Disease (PD), today previewed the results of an ongoing nine-month research program involvin
Source: www.businesswire.comCategories: General Medicine News, Hem/OncsTweet-
Rune Labs’ StrivePD Nearly Halves ER Visits for Parkinson’s Patients in Program w Kaiser Permanente @aboutKP @Apple @RuneLabsCEO 42% reduction in ER visits 18% ⬇️ in specialists’ time 90% of pts ⬆️ exercise 80% better adherence ✅ https://t.co/JzdQDeWfJv
-
FDA Approves Optune Lua for Metastatic NSCLC After Platinum-Based Chemotherapy https://t.co/c0UM26tVee via @onclive